Aim: The knowledge level of nurses plays a key role in preventing medical device-related pressure injuries. This research aimed to investigate the knowledge levels of nurses with regard to medical device-related pressure injuries and the factors affecting these.
Materials And Methods: This descriptive and cross-sectional study was conducted with 355 nurses between December 15, 2020 and March 31, 2021. Data were collected using the Nurse Information Form and the Medical Device-Related Pressure Injuries Knowledge Questionnaire.
Results: The mean score of the nurses for the Medical Device-Related Pressure Injuries Knowledge Questionnaire was 22.11 ± 5.79. The nurses obtained the highest score from the "Description" sub-dimension of the test, whereas the lowest scores pertained to the "Staging" sub-dimension. Only 23.1% of the nurses stated that they had general knowledge about medical device-related pressure injuries. A significant difference was determined between the mean scores that the nurses got from the Medical Device-Related Pressure Injuries Knowledge Questionnaire and their gender, work experience in the intensive care unit, frequency of encountering a medical device-related pressure injuries and their previous training on such injuries. In addition, a positive relationship was determined between the level of knowledge about medical device-related pressure injuries and age and seniority.
Results: It was concluded that the level of knowledge of nurses about medical device-related pressure injuries was insufficient. We therefore recommend that a regular training program be provided to nurses on medical device-related pressure injuries in order to reduce the incidence of these injuries and to provide a quality and safe care service to patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jtv.2022.01.006 | DOI Listing |
Med Decis Making
December 2024
University of California, San Francisco School of Medicine, San Francisco, CA, USA.
Background: After a new drug or medical device is approved by the US Food and Drug Administration (FDA), physician-patient communication about benefits and risks is critical, including whether the product was approved through an expedited pathway based on limited evidence. In addition, physician reporting of drug- and device-related adverse events in real-world use is necessary to have a complete safety profile. We studied physician-reported communication and safety-reporting practices related to drugs and devices.
View Article and Find Full Text PDFDig Dis Sci
December 2024
Surgical Department, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Background: RefluxStop is a unique implant for laparoscopic treatment of gastroesophageal reflux disease (GERD). It restores normal function of the gastroesophageal junction without the unwanted effects of encircling the esophagus, circumventing adverse events (AEs) associated with conventional anti-reflux surgeries.
Methods: Three-year follow-up of 50 patients with chronic GERD treated by RefluxStop was achieved in a prospective, single-arm, multicentric clinical trial analyzing safety and effectiveness of the procedure.
Ann Vasc Surg
December 2024
Division of Vascular and Endovascular surgery, St. Elizabeth's Medical Center, Boston, Massachusetts.
Objective: Thoracic endovascular repair (TEVAR) has become the treatment of choice for acute, complicated type B aortic dissections. The purpose of this study was to evaluate the 5-year outcomes of the GORE TAG 08-01 study on TEVAR for acute, complicated type B aortic dissections using the Conformable GORE® TAG® Thoracic Endoprosthesis (CTAG), and to establish if late aortic complications are avoided and remodeling is sustained.
Methods: From January 2010 to February 2017, 50 patients with acute, complicated type B aortic dissections were enrolled from 26 sites in the U.
J Tissue Viability
December 2024
Faculty of Health Science, Nursing Department, Atılım University, 06830, Ankara, Türkiye. Electronic address:
Clin Case Rep
December 2024
Department of Cardiothoracic Surgery HonorHealth Scottsdale Arizona USA.
Patent foramen ovale (PFO) closure using percutaneous devices, such as the Amplatzer occluder, is a common treatment for patients with a history of cryptogenic stroke or transient ischemic attack (TIA). Although generally well-tolerated, some patients may develop adverse reactions to the device materials, particularly in the presence of a nickel allergy. Symptoms can include chest pain, rashes, and migraines, which may necessitate surgical removal of the device.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!